NASDAQ · Biotechnology

Olema Pharmaceuticals, Inc. (OLMA) Stock

$7.82 +0.00% NASDAQ: OLMA Healthcare

Valuation

MetricValue
Price$7.82
Market Cap$683.06M
P/E Ratio-3.81
P/B Ratio1.96
P/S Ratio0.00
EPS (TTM)$-2.54
52-Week High$36.26
52-Week Low$6.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-48.22%
ROA-42.04%
ROCE-51.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio9.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-71.0M$-107.0M$-105.0M$-142.0M$-179.0M
Net Profit$-71.0M$-105.0M$-97.0M$-129.0M$-162.0M
EPS$-1.79$-2.62$-2.14$-2.20$-1.87
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$296.0M$216.0M$277.0M$451.0M$533.0M
Total Liabilities$11.0M$18.0M$23.0M$42.0M$55.0M
Cash$14.0M$24.0M$69.0M$139.0M$48.0M
Borrowings$3.0M$3.0M$2.0M$1.0M$1.0M

Latest News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? Simply Wall St. · Jun 30, 2026 How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet Insider Monkey · Jun 17, 2026 Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy MT Newswires · May 26, 2026 Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer GlobeNewswire · May 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-51.0M$-82.0M$-84.0M$-104.0M$-147.0M
Investing Cash Flow$-277.0M$91.0M$-5.0M$-94.0M$-156.0M
Financing Cash Flow$0$0$4.0M$3.0M$0
Net Cash Flow$-325.0M$10.0M$45.0M$71.0M$-91.0M
Free Cash Flow$-52.0M$-82.0M$-84.0M$-105.0M$-147.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.74
EV / EBITDA-3.22
FCF Yield-23.37%
Quick Ratio8.86
Interest Coverage0.00
Return 1Y151.93%
Return 3Y29.72%
Return 5Y-52.41%

Ownership

Insiders Held1.80%
Institutions Held119.34%
Institutions Float Held121.52%
Institutional HolderSharesReport Date
FMR, LLC10,386,8452026-03-31
Paradigm Biocapital Advisors LP8,020,5762026-03-31
Bain Capital Life Sciences Investors, LLC7,473,2382026-03-31
Janus Henderson Group PLC7,108,4882026-03-31
Blackrock Inc.5,652,1352026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
PBYIPuma Biotechnology Inc $10.29 +3.21% 17.55 $523.76M 0.00%

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. is led by CEO Sean Bohen, employs 96 people, headquartered in US, publicly traded since 2020.

Olema Pharmaceuticals, Inc. (OLMA) stock trades at $7.82 with a market capitalization of $683.06M. The stock is valued at a price-to-earnings (P/E) ratio of -3.81, price-to-book of 1.96, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $6.65 and $36.26, and currently trades 78.4% below its 52-week high.

On profitability, Olema Pharmaceuticals, Inc. generates a return on equity (ROE) of -48.22%, return on capital employed of -51.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides